Bruceine D suppresses osteoclast formation and protects bone in ovariectomized mice

Bruceine D reduced the formation and bone-resorbing activity of osteoclasts in cell cultures and improved trabecular bone architecture in an ovariectomy mouse model of estrogen-deficiency-induced osteoporosis. The preclinical study linked these effects to reduced signaling through STAT3 and NF-κB, accompanied by lower expression of the osteoclast-associated transcription factor NFATc1; it did not test human participants. Investigators tested Bruceine D in two experimental systems.

In vitro, they stimulated bone marrow-derived macrophages with RANKL to induce osteoclast differentiation, with or without Bruceine D. Treatment suppressed the formation of multinucleated osteoclasts in a dose-dependent manner. The effective concentrations were not reported as cytotoxic.

TRAP staining was used to assess osteoclast formation, while quantitative reverse-transcription PCR and western blotting were used to examine gene and protein expression. Multiple cellular measurements were consistent with inhibited osteoclast development. It also reduced the cells’ bone-resorption activity.

At the molecular level, the compound attenuated STAT3 and NF-κB signaling without affecting the tested MAPK and AKT pathways. The reduced signaling was associated with downregulation of NFATc1, a key transcription factor in osteoclastogenesis, leading the authors to identify the STAT3/NF-κB/NFATc1 axis as the mechanism implicated in the observed effects. The researchers next evaluated Bruceine D in an ovariectomy model of osteoporosis.

Ovariectomy produces estrogen deficiency and bone loss in mice, allowing the investigators to examine protection against deterioration of bone microarchitecture. Bruceine D treatment markedly alleviated trabecular bone loss, with improved bone-microarchitecture parameters reported in treated animals. These results show a protective effect in this mouse model and align with the compound’s inhibition of osteoclast formation and activity observed in cultured cells.

The evidence is limited to laboratory cultures and an ovariectomized mouse model, so the findings do not establish that Bruceine D is safe or effective for treating postmenopausal osteoporosis in humans. The supplied study abstract also does not provide the numerical concentrations, treatment schedules or effect sizes needed to assess the magnitude and reproducibility of the reported responses. Within those limits, the study provides convergent cellular, molecular and animal evidence that Bruceine D can suppress osteoclastogenesis and reduce estrogen-deficiency-associated trabecular bone loss under experimental conditions.

Subject of Research: Preclinical evaluation of Bruceine D for suppressing osteoclast formation and protecting against estrogen-deficiency-associated bone loss

Article Title: Bruceine D suppressed osteoclast formation via STAT3/NF-κB/NFATc1 signaling and protected postmenopausal osteoporosis

Article References: Lin, S., Yuan, Q., Yao, X., & Nie, X. (2026). Bruceine D suppressed osteoclast formation via STAT3/NF-κB/NFATc1 signaling and protected postmenopausal osteoporosis. Molecular Biology Reports, 53(1), Article 1508. https://doi.org/10.1007/s11033-026-12677-y

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12677-y

Keywords: Bruceine D, osteoclast formation, osteoclastogenesis, bone resorption, postmenopausal osteoporosis, ovariectomy model, STAT3 signaling, NF-κB signaling, NFATc1, bone microarchitecture, preclinical research, Bruceine